SWOG clinical trial number
SWOG-8594

A Phase III Trial of Cisplatin Alone or in Combination with Doxorubicin, Vinblastine and Methotrexate in Advanced Bladder Cancer

Closed
Phase
Published
Abbreviated Title
A Phase III Trial of Cisplatin Alone or in Combination with Doxorubicin, Vinblastine and Methotrexate in Advanced Bladder Cancer
Activated
10/01/1984
Closed
05/15/1989

Research committees

Genitourinary Cancer

Publication Information Expand/Collapse

1997

Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study.

SB Saxman;KJ Propert;LH Einhorn;ED Crawford;I Tannock;D Raghavan;PJ Loehrer Sr;D Trump Journal of Clinical Oncology 15(7):2564-2569

1992

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A Cooperative Group Study.

PJ Loehrer, Sr;LH Einhorn;PJ Elson;ED Crawford;P Kuebler;I Tannock;D Raghaven;R Stuart-Harris;MF Sarosdy;BA Lowe;B Blumenstein;D Trump JCO 10(17):1066-1073

1990

Advanced bladder cancer: A prospective intergroup trial comparing single agent cisplatin (CDDP) vs. M-VAC combination therapy (INT-0078).

PJ Loehrer;P Elson;JP Kuebler;ED Crawford;I Tannock;D Raghavan;R Stuart-Harris;D Trump;LH Einhorn ASCO 9:132(#511)

Other Clinical Trials

SWOG Clinical Trial Number
S2312

A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2210

S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
7%
Open
Phase
SWOG Clinical Trial Number
S2200

S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
14%
Open
Phase